2m 2m 2m 2m 2m 2m 2m
- $7.8BMarket Cap
- 7.94%1-Year Change
- Medical DevicesIndustry
Bio-Rad Lab-A (BIO)
Key Performance
More- Earnings Score: 35
- Momentum Score: 74
- True Yield: N/A
- Financial Health Score: 50
Latest Research & News
The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.
10/06/2026, 4:54 AM • GlobeNewswire
Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.
10/05/2026, 10:00 AM • GlobeNewswire
The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.
10/05/2026, 6:45 AM • GlobeNewswire
The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.
10/05/2026, 4:58 AM • GlobeNewswire
The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.
09/30/2026, 4:56 AM • GlobeNewswire
The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.
09/28/2026, 10:00 AM • GlobeNewswire
The global Therapeutic Drug Monitoring (TDM) consumables market is projected to grow from USD 364.27 million in 2026 to USD 586.85 million by 2032, driven by an 8.22% CAGR. Growth is fueled by AI-enabled automation, integrated lab workflows, standardized collection devices, and improved specimen integrity. Key drivers include workflow integration, digital connectivity, and responsible AI governance across diverse regional markets with distinct operational priorities.
09/28/2026, 4:58 AM • GlobeNewswire
The global metabolomics market is projected to grow from USD 2.81 billion in 2025 to USD 9.01 billion by 2035, expanding at a CAGR of 12.36%. Growth is driven by precision medicine, biomarker discovery, and multiomics adoption, with oncology accounting for over 44% of the market. However, Q1 2026 faced challenges from geopolitical tensions, supply chain disruptions, and elevated logistics costs affecting laboratory budgets and procurement timelines.
09/22/2026, 8:00 AM • GlobeNewswire
The global magnetic bead purification kits market reached $4.08 billion in 2025 with an 11.6% CAGR and is projected to grow to $6.73 billion by 2030 (10.5% CAGR) and $10.42 billion by 2035 (9.1% CAGR). Growth is driven by expanding genomics research, molecular diagnostics, and high-throughput screening. Semi-automated kits dominate at 51.8% market share, while Asia-Pacific is the fastest-growing region at 12% CAGR. Key challenges include skilled labor shortages and automation infrastructure dependencies.
09/21/2026, 4:56 AM • GlobeNewswire
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
09/04/2026, 5:48 AM • GlobeNewswire
The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.
08/27/2026, 1:00 PM • GlobeNewswire
Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.
08/06/2026, 10:52 AM • GlobeNewswire
The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.
07/24/2026, 9:30 AM • GlobeNewswire
The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and Europe $19.32 billion by 2035, with Asia-Pacific showing the fastest growth.
07/03/2026, 6:48 AM • GlobeNewswire
Oxidative Stress Assay Market Size to Reach USD 3.25 Billion by 2035 | SNS Insider
The global Oxidative Stress Assay Market is projected to grow at a CAGR of 9.53% from 2026 to 2035, driven by rising chronic disease prevalence, pharmaceutical R&D investments, and advancements in biomarker diagnostics. North America leads with 38.52% market share, while Asia-Pacific is expected to show the highest growth rate at 10.55%. ELISA technology dominates with 39% market share, and cancer research accounts for 33% of revenue.
06/28/2026, 10:30 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/21/2026
Company Profile
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Key Executives
- Norman D. Schwartz
- Jonathan DiVincenzo
- James J. Barry
- Roop K. Lakkaraju
- Michael Crowley
Current Ownership Distribution
- Institutions368.0M (54.13%)
- Mutual Funds309.0M (45.44%)
- Insiders3.0M (0.44%)
- Other0 (0.00%)